What happened
Shares of the Chinese anti-cancer cell therapy specialist Legend Biotech (NASDAQ: LEGN) are poised for a rough session today. Ahead of the opening bell Monday morning, the biotech's stock fell by as much as 15.8% in response to the news that the Customs Anti-Smuggling Department of the People's Republic of China (PRC) inspected offices associated with both its parent majority shareholder, GenScript Biotech Corporation, and some of its own subsidiaries in the country.
Legend said this customs inspection appears to be related to suspected violations of import and export regulations under the laws of the PRC. As part of this investigation, the biotech's Chief Executive Officer, Fangliang Zhang, has reportedly been placed under residential surveillance by PRC law enforcement. In response, Legend has named its current Chief Financial Officer, Ying Huang, as interim CEO, effective immediately.
Image source: Getty Images.
So what
While it's not altogether clear how this investigation will impact the biotech's all-important collaboration with Johnson & Johnson for the experimental multiple myeloma therapy cilta-cel (aka JNJ-4528), investors rarely like to see a company come under scrutiny by a governmental agency of any kind. And this rule of thumb arguably applies doubly so for Chinese companies due to the lack of transparency within the PRC in general.
Now what
Legend's core investing thesis isn't sunk by any stretch of the imagination. But this customs investigation -- until it is resolved one way or another -- is almost certainly going to weigh on the biotech's shares. Bargain hunters, in turn, may want to watch this beaten-down biotech stock from the safety of the sidelines for now.
10 stocks we like better than Legend Biotech Corporation
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Legend Biotech Corporation wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 1, 2020
George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
